Showing 151-160 of 842 results for "".
RF Technologies: What should you know?
https://practicaldermatology.com/videos/scientifically-speaking/rf-technologies-what-should-you-know/19848/With so many radiofrequency devices now on the market and new ones in development, aesthetic specialists need to know how to select the proper tool for each patient need. E. Victor Ross, MD and Erez Dayan, MD join host Joel L. Cohen, MD to go beyond the marketing jargon to assess the science and cliMind Your Mannerisms
https://practicaldermatology.com/topics/practice-management/mind-your-mannerisms/20540/Body language can have a lot to do with establishing rapport and trust and supporting long-term adherence.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eInbound Marketing: Why You Need a Strategy
https://practicaldermatology.com/topics/practice-management/inbound-marketing/18782/Focus on cultivating interactive marketing messages to show your audience what your practice is all about and what value it offers your target audience. "In your face" marketing is a thing of the past. Learn three strategies for successful inbound marketing for a medical practice in this Ekwa.com EJournal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EThe Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and cClinical Insights on Management of Comorbidities in the Psoriasis Patient
https://practicaldermatology.com/topics/psoriasis/clinical-insights-on-management-of-comorbidities-in-the-psoriasis-patient/21375/As psoriasis is associated with an increasing number of comorbidities, clinicians discuss their approach to management focused on the whole patient.Positive Energy
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/positive-energy/23850/Energy-based devices offer cosmetic patients visible results with minimal downtime.In the Pipeline: What to Know About Tapinarof
https://practicaldermatology.com/topics/psoriasis/in-the-pipeline-what-to-know-about-tapinarof/23320/Here’s a closer look at the novel topical being studied for psoriasis and atopic dermatitis.Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.